STELLAR Failure Prompts Cell Therapeutics To Amend Next Xyotax Trial

Positive non-inferiority to standard paclitaxel is silver lining to STELLAR 3, firm says. Potential amendment to the second-line STELLAR 2 trial to use non-inferiority as the primary endpoint will be discussed with FDA. CTI plans to present results from STELLAR 3 at ASCO meeting in May.